CO2023017275A2 - Composición farmacéutica para tratar o prevenir un trastorno relacionado con la administración de un agente anticancerígeno - Google Patents

Composición farmacéutica para tratar o prevenir un trastorno relacionado con la administración de un agente anticancerígeno

Info

Publication number
CO2023017275A2
CO2023017275A2 CONC2023/0017275A CO2023017275A CO2023017275A2 CO 2023017275 A2 CO2023017275 A2 CO 2023017275A2 CO 2023017275 A CO2023017275 A CO 2023017275A CO 2023017275 A2 CO2023017275 A2 CO 2023017275A2
Authority
CO
Colombia
Prior art keywords
pharmaceutical composition
administration
anticancer agent
treating
preventing
Prior art date
Application number
CONC2023/0017275A
Other languages
English (en)
Spanish (es)
Inventor
Zhiwei Qiao
Manami Honda
Shouta Akimoto
Tomoki Sasaki
Noriko Kaji
Koichiro Fukuda
Tohru Mizushima
Ken-Ichiro Tanaka
Original Assignee
Ltt Bio Pharma Co Ltd
Musashino Univ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ltt Bio Pharma Co Ltd, Musashino Univ filed Critical Ltt Bio Pharma Co Ltd
Publication of CO2023017275A2 publication Critical patent/CO2023017275A2/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/555Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/243Platinum; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44Oxidoreductases (1)
    • A61K38/446Superoxide dismutase (1.15)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544Phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/548Phosphates or phosphonates, e.g. bone-seeking
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004Oxidoreductases (1.)
    • C12N9/0089Oxidoreductases (1.) acting on superoxide as acceptor (1.15)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y115/00Oxidoreductases acting on superoxide as acceptor (1.15)
    • C12Y115/01Oxidoreductases acting on superoxide as acceptor (1.15) with NAD or NADP as acceptor (1.15.1)
    • C12Y115/01001Superoxide dismutase (1.15.1.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CONC2023/0017275A 2021-05-18 2023-12-14 Composición farmacéutica para tratar o prevenir un trastorno relacionado con la administración de un agente anticancerígeno CO2023017275A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2021083610 2021-05-18
PCT/JP2022/020473 WO2022244757A1 (ja) 2021-05-18 2022-05-17 抗癌剤の投与に伴う障害を治療又は予防するための医薬組成物

Publications (1)

Publication Number Publication Date
CO2023017275A2 true CO2023017275A2 (es) 2023-12-20

Family

ID=84141593

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2023/0017275A CO2023017275A2 (es) 2021-05-18 2023-12-14 Composición farmacéutica para tratar o prevenir un trastorno relacionado con la administración de un agente anticancerígeno

Country Status (11)

Country Link
US (1) US20240261375A1 (https=)
EP (1) EP4353251A4 (https=)
JP (1) JP7504367B2 (https=)
KR (1) KR102843447B1 (https=)
CN (1) CN117279657A (https=)
AU (1) AU2022278242B2 (https=)
CA (1) CA3220333A1 (https=)
CO (1) CO2023017275A2 (https=)
MX (1) MX2023013777A (https=)
TW (1) TWI867299B (https=)
WO (1) WO2022244757A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025178511A1 (ru) * 2024-02-21 2025-08-28 Евгений Владимирович ГРИГОРЬЕВ Применение супероксиддисмутазы 2 в качестве антиоксиданта в сверхмалых дозировках

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0653670B2 (ja) * 1985-10-28 1994-07-20 日研フ−ド株式会社 化学療法剤の副作用低減化剤
JPH04135485A (ja) * 1990-09-28 1992-05-08 Seikagaku Kogyo Co Ltd 白金錯体及び抗腫瘍剤
JP3232542B2 (ja) 1993-01-08 2001-11-26 宇部興産株式会社 ヒトCu,Zn型スーパーオキシドジスムターゼ誘導体及びその製造法
JPH08208511A (ja) * 1995-01-31 1996-08-13 Samu Kenkyusho:Kk 抗運動ニューロン疾患剤
US6221848B1 (en) * 1998-05-11 2001-04-24 University Of Pittsburgh Protection of the esophagus from chemotherapeutic or irradiation damage by gene therapy
US20020055467A1 (en) 1998-07-06 2002-05-09 Johansen Teit E. Novel neurotrophic factors
JP2001002585A (ja) * 1999-06-22 2001-01-09 Ltt Kenkyusho:Kk レシチン化スーパーオキシドジスムターゼ含有抗線維化剤
JP3792487B2 (ja) 1999-06-24 2006-07-05 株式会社Lttバイオファーマ レシチン化スーパーオキシドジスムターゼ含有医薬組成物
JP2003532691A (ja) 2000-05-05 2003-11-05 ノボ ノルディスク アクティーゼルスカブ 重症疾患神経障害
JP2002080395A (ja) * 2000-08-31 2002-03-19 Ltt Institute Co Ltd 心筋傷害処置剤
ES2375797T3 (es) 2003-01-21 2012-03-06 Genervon Biopharmaceuticals Llc Péptidos y compuestos de factores tróficos de motoneuronas y sus procedimientos de utilización.
JP4958556B2 (ja) * 2004-10-12 2012-06-20 株式会社Lttバイオファーマ レシチン化スーパーオキシドディスムターゼ組成物およびその製造方法
WO2006050211A2 (en) 2004-10-28 2006-05-11 University Of Pittsburgh Of The Commonwealth System Of Higher Education Peripherally delivered glutamic acid decarboxylase gene therapy for spinal cord injury pain
JP2006169128A (ja) 2004-12-13 2006-06-29 Ltt Bio-Pharma Co Ltd 熱傷治療剤
JP4867540B2 (ja) 2006-09-20 2012-02-01 日本精工株式会社 無段変速装置
US20100143321A1 (en) * 2006-12-19 2010-06-10 Ltt Bio Pharma Co., Ltd. Therapeutic composition for interstitual pneumonia
JP5459827B2 (ja) 2009-03-13 2014-04-02 株式会社Lttバイオファーマ 慢性閉塞性肺疾患改善剤
EP2637698B1 (en) 2010-11-09 2022-04-20 Novo Nordisk A/S Double-acylated glp-1 derivatives
US9187509B2 (en) 2012-01-05 2015-11-17 Pled Pharma AB Calmangafodipir, a new chemical entity, and other mixed metal complexes, methods of preparation, compositions, and methods of treatment
JP6545926B2 (ja) * 2012-11-30 2019-07-17 株式会社ナノエッグ 手足症候群治療用組成物
RU2017106172A (ru) 2014-07-31 2018-08-28 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Применение антагонистов cxcr2 для предотвращения и/или лечения периферической невропатии, вызванной химиотерапией (cipn)
EP2985036A3 (en) 2014-08-14 2016-03-09 Fraunhofer Gesellschaft zur Förderung der angewandten Forschung e.V. CYP2J2 antagonists in the treatment of pain
US11197862B2 (en) 2015-07-16 2021-12-14 Xomics Biopharma, Inc. Methods of preventing toxicity of platinum drugs
JP6650612B2 (ja) 2015-10-06 2020-02-19 パナソニックIpマネジメント株式会社 照明制御装置及び照明システム

Also Published As

Publication number Publication date
EP4353251A1 (en) 2024-04-17
CN117279657A (zh) 2023-12-22
US20240261375A1 (en) 2024-08-08
JP7504367B2 (ja) 2024-06-24
AU2022278242B2 (en) 2024-11-14
MX2023013777A (es) 2023-12-04
TW202313100A (zh) 2023-04-01
WO2022244757A1 (ja) 2022-11-24
KR20240008844A (ko) 2024-01-19
JPWO2022244757A1 (https=) 2022-11-24
BR112023024140A2 (pt) 2024-02-06
TWI867299B (zh) 2024-12-21
AU2022278242A1 (en) 2023-11-30
EP4353251A4 (en) 2025-05-14
KR102843447B1 (ko) 2025-08-06
CA3220333A1 (en) 2022-11-24

Similar Documents

Publication Publication Date Title
CL2023000846A1 (es) Terapia de combinación que incluye inhibidor de krasg12c y agente farmacéuticamente activo para tratar cáncer
MX2023009521A (es) Compuesto de quinazolina para inducir la degradacion de la proteina kras mutante g12d.
BR112020017090A8 (pt) Imunoterapias relacionadas com microbioma
BRPI0809164B8 (pt) Composição para administração tópica e composição farmacêutica compreendendo a referida composição
PE20180394A1 (es) Composiciones que comprenden una combinacion de un anticuerpo anti muerte programada 1 (pd-1) y otro anticuerpo
BR112019008431A2 (pt) aplicação de (s)-norcetamina e sal da mesma como fármaco
MX2023013403A (es) Composicion farmaceutica para prevenir o tratar la fibrosis.
AR071003A1 (es) Farmaco contra cancer de higado
BR112018008601A2 (pt) composições compreendendo o canabidiol e segundos agentes terapêuticos para o tratamento de câncer
MX2023006504A (es) Compuesto de hidroxamato, metodo de preparacion del mismo y aplicacion del mismo.
BR112018076639A2 (pt) quimioterapias de combinação
CL2025001707A1 (es) Dispersión sólida de un inhibidor de her2.
BR112018072201A2 (pt) composição compreendendo o componente à base de naftoquinona como ingrediente ativo, para prevenir ou melhorar a fadiga, cachexia, dor, declínio cognitivo e redução de células estaminais hematopoiéticas que são efeitos colaterais relacionados as drogas para tratamento anticancerígino
CO2023017275A2 (es) Composición farmacéutica para tratar o prevenir un trastorno relacionado con la administración de un agente anticancerígeno
BR112022007998A2 (pt) Novo composto e composição farmacêutica para prevenção ou tratamento de câncer que compreende os mesmos
BR112022018396A2 (pt) Método de tratamento ou prevenção para insuficiência cardíaca crônica
CO2024005469A2 (es) Compuesto de óxido de fenilarsina halogenado y aplicación del mismo
MX2018015893A (es) Compuestos anti-cancer.
MX2018015916A (es) Compuestos de porfirina y composiciones útiles para el tratamiento de cáncer.
MX2018002681A (es) Agente mejorador de la inmunidad contra el cancer por el antagonista de "allergin-1".
BR112022026558A2 (pt) Novo composto e composição farmacêutica para prevenir ou tratar câncer resistente que compreende o mesmo
CL2025001708A1 (es) Esquema de dosificación de una dispersión sólida de un inhibidor de her2
MX2019006940A (es) Uso de compuestos de carbamato para prevencion, alivio o tratamiento del trastorno bipolar.
NI201900128A (es) Combinación de un inhibidor de mcl-1 y un tratamiento de atención estándar para cáncer hematológico, usos y composiciones farmacéuticas de esta
AR126552A1 (es) Composición farmacéutica para prevenir o tratar la esclerosis sistémica